{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:12:35Z","timestamp":1772255555372,"version":"3.50.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejps.2023.106475","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:37:45Z","timestamp":1684755465000},"page":"106475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes"],"prefix":"10.1016","volume":"187","author":[{"given":"Jacqueline Wen Hui","family":"Leow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9072","authenticated-orcid":false,"given":"Eric Chun Yong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106475_bib0079","series-title":"Product Monograph: Ondansetron Injection","year":"2020"},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0066","doi-asserted-by":"crossref","first-page":"8C","DOI":"10.1016\/0002-9149(85)90799-4","article-title":"Pharmacokinetics and metabolism of bepridil","volume":"55","author":"Benet","year":"1985","journal-title":"Am. J. Cardiol."},{"issue":"9","key":"10.1016\/j.ejps.2023.106475_bib0003","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/FPC.0b013e32810f2e58","article-title":"Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues","volume":"17","author":"Bi\u00e8che","year":"2007","journal-title":"Pharmacogenet. Genom."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0054","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1506","article-title":"Positron emission tomography imaging of [11 C] rosuvastatin hepatic concentrations and hepatobiliary transport in humans in the absence and presence of cyclosporin A","volume":"106","author":"Billington","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"13","key":"10.1016\/j.ejps.2023.106475_bib0049","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejps.2023.106475_bib0099","doi-asserted-by":"crossref","unstructured":"Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. 1985;232(3).","DOI":"10.1016\/S0022-3565(25)20919-3"},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1159\/000354513","article-title":"Factors involved in extracellular matrix turnover in human derived cardiomyocytes","volume":"32","author":"Casals","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0042","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14740338.4.3.509","article-title":"ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis","volume":"4","author":"Cavero","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0045","first-page":"745","article-title":"Comprehensive in vitro Proarrhythmia Assay, a novel in vitro\/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative","volume":"13","author":"Cavero","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejps.2023.106475_bib0035","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1096\/fasebj.2018.32.1_supplement.833.9","article-title":"CYP2J2 inhibition: the arcane mechanism of dronedarone-induced proarrhythmia","volume":"32","author":"Chan","year":"2018","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.ejps.2023.106475_bib0121","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/pds.3814","article-title":"Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study","volume":"24","author":"Chen","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0103","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2133\/dmpk.24.261","article-title":"Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources","volume":"24","author":"Christensen","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00498254.2010.523734","article-title":"CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity","volume":"41","author":"Christensen","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2023.106475_bib0046","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1573403X12666160301120217","article-title":"Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias","volume":"12","author":"Cubeddu","year":"2016","journal-title":"Curr. Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0059","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.yjmcc.2005.03.003","article-title":"Novel cell lines derived from adult human ventricular cardiomyocytes","volume":"39","author":"Davidson","year":"2005","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.ejps.2023.106475_bib0051","doi-asserted-by":"crossref","unstructured":"Di L., Riccardi K., Tess D. Evolving approaches on measurements and applications of intracellular free drug concentration and Kpuu in drug discovery. https:\/\/doi-org.libproxy1.nus.edu.sg\/101080\/1742525520211935866. 2021;17(7):733\u2013746. doi:10.1080\/17425255.2021.1935866.","DOI":"10.1080\/17425255.2021.1935866"},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0113","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0149-2918(00)88286-7","article-title":"Second-generation antihistamines: the risk of ventricular arrhythmias","volume":"21","author":"DuBuske","year":"1999","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0006","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1124\/dmd.109.027011","article-title":"Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function","volume":"37","author":"Dutheil","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0097","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.yjmcc.2011.09.021","article-title":"Molecular determinants of hERG potassium channel inhibition by disopyramide","volume":"52","author":"El Harchi","year":"2012","journal-title":"J. Mol. Cell Cardiol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pharmthera.2005.05.011","article-title":"Cytochrome P450 enzymes: central players in cardiovascular health and disease","volume":"112","author":"Elbekai","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106475_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fphys.2017.00043","article-title":"Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels","volume":"8","author":"Elinder","year":"2017","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.ejps.2023.106475_bib0004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/002215540405200403","article-title":"Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues","volume":"52","author":"Enayetallah","year":"2004","journal-title":"J. Histochem. Cytochem."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/jox11030007","article-title":"The central role of cytochrome P450 in xenobiotic metabolism\u2014a brief review on a fascinating enzyme family","volume":"11","author":"Esteves","year":"2021","journal-title":"J. Xenobiot."},{"issue":"12","key":"10.1016\/j.ejps.2023.106475_bib0087","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.113.053389","article-title":"Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes","volume":"41","author":"Evangelista","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106475_bib0089","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.2147\/CMAR.S127848","article-title":"Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes","volume":"11","author":"Fallahi","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0119","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40495-017-0082-5","article-title":"Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a minireview illustrating recent developments and current opportunities","volume":"3","author":"Fowler","year":"2017","journal-title":"Curr. Pharmacol. Rep."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3945\/an.114.007732","article-title":"Advances in our understanding of oxylipins derived from dietary PUFAs","volume":"6","author":"Gabbs","year":"2015","journal-title":"Adv. Nutr."},{"issue":"9","key":"10.1016\/j.ejps.2023.106475_bib0037","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.31.9.1108","article-title":"Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine","volume":"31","author":"Galetin","year":"2003","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0047","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2023.106475_bib0123","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.compbiomed.2014.01.010","article-title":"The effects of six antipsychotic agents on QTc\u2013an attempt to mimic clinical trial through simulation including variability in the population","volume":"47","author":"Glinka","year":"2014","journal-title":"Comput. Biol. Med."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0082","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00004714-199812000-00010","article-title":"Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia","volume":"18","author":"Guitton","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0064","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/dmd.119.086611","article-title":"Overview of the components of cardiac metabolism","volume":"47","author":"Hausner","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0023","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cvr\/cvv018","article-title":"Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II","volume":"105","author":"He","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79952-1","article-title":"Differential effects on human cytochromes P450 by CRISPR\/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells","volume":"11","author":"Heintze","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0107","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1124\/mol.112.084616","article-title":"Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system","volume":"83","author":"Henderson","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0071","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF03189516","article-title":"On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration","volume":"6","author":"Heykants","year":"1981","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"1\u20134","key":"10.1016\/j.ejps.2023.106475_bib0081","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ddr.430080109","article-title":"Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man","volume":"8","author":"Heykants","year":"1986","journal-title":"Drug Dev. Res."},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0091","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1476-5381.1988.tb11436.x","article-title":"Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea-pig papillary muscle","volume":"93","author":"Hondeghem","year":"1988","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0116","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106475_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2019.04.005","article-title":"Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: potent inhibition by azelnidipine and manidipine","volume":"306","author":"Ikemura","year":"2019","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0083","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ams2.277","article-title":"Two cases of life-threatening arrhythmia induced by risperidone: evaluation of risperidone and 9-hydroxy-risperidone concentrations","volume":"4","author":"Ito","year":"2017","journal-title":"Acute Med. Surg."},{"key":"10.1016\/j.ejps.2023.106475_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.05.005","article-title":"Cytochrome P450-derived eicosanoids and heart function","volume":"179","author":"Jamieson","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106475_bib0129","first-page":"153","article-title":"Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes","author":"Jarrar","year":"2020","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0053","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1124\/dmd.118.080408","article-title":"A clinical quantitative evaluation of hepatobiliary transport of [11 C] dehydropravastatin in humans using positron emission tomography","volume":"46","author":"Kaneko","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.ejps.2023.106475_bib0032","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/j.1875-9114.2012.01118.x","article-title":"Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting","volume":"32","author":"Kao","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2023.106475_bib0033","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2016.03.005","article-title":"Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites","volume":"107","author":"Karkhanis","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106475_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2017.02.017","article-title":"Inhibition and inactivation of human CYP2J2: implications in cardiac pathophysiology and opportunities in cancer therapy","volume":"135","author":"Karkhanis","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106475_bib0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2017.09.012","article-title":"Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids","volume":"146","author":"Karkhanis","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106475_bib0034","article-title":"Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts","volume":"16","author":"Karkhanis","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.ejps.2023.106475_bib0021","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1124\/mol.107.035881","article-title":"Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice","volume":"72","author":"Ke","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.2009.03469.x","article-title":"Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs","volume":"68","author":"Knights","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2023.106475_bib0040","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106475_bib0095","doi-asserted-by":"crossref","unstructured":"Koumi S.I., Sato R., Hisatome I., Hayakawa H., Okumura H., Katori R. Disopyramide block of cardiac sodium current after removal of the fast inactivation process in guinea pig ventricular myocytes. 1992;261(3).","DOI":"10.1016\/S0022-3565(25)11134-8"},{"issue":"10","key":"10.1016\/j.ejps.2023.106475_bib0086","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.bmcl.2006.02.004","article-title":"Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2","volume":"16","author":"Lafite","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2023.106475_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.642470","article-title":"The role of epoxyeicosatrienoic acids in cardiac remodeling","volume":"12","author":"Lai","year":"2021","journal-title":"Front. Physiol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0112","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1023\/A:1016036624935","article-title":"Population pharmacokinetics of terfenadine","volume":"13","author":"Lalonde","year":"1996","journal-title":"Pharm. Res."},{"issue":"Pt 1","key":"10.1016\/j.ejps.2023.106475_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1469-7793.1999.0153o.x","article-title":"Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes","volume":"519","author":"Lee","year":"1999","journal-title":"J. Physiol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0036","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/dmd.109.030270","article-title":"Identification of novel substrates for human cytochrome P450 2J2","volume":"38","author":"Lee","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0029","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/bja\/61.3.297","article-title":"Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia","volume":"61","author":"Lehmann","year":"1988","journal-title":"Br. J. Anaesth."},{"issue":"17","key":"10.1016\/j.ejps.2023.106475_bib0088","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2023.106475_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106654","article-title":"Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure","volume":"101","author":"Leishman","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejps.2023.106475_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.017","article-title":"Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: a focus on substrate inhibition","volume":"169","author":"Leow","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106475_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105889","article-title":"Atypical kinetics of cytochrome P450 2J2: epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors","volume":"164","author":"Leow","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2023.106475_bib0109","doi-asserted-by":"crossref","unstructured":"Leow J.W.H., Tang L.W.T., Chan E.C.Y. Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology. In: Yamazaki H, ed. Pharmacology and Toxicology of Cytochrome P450 - 60th Anniversary. Advances in Pharmacology. Vol 95. 1st ed. Academic Press; 2022.","DOI":"10.1016\/bs.apha.2021.12.001"},{"key":"10.1016\/j.ejps.2023.106475_bib0039","doi-asserted-by":"crossref","unstructured":"Lepist E.I., Ray A.S. Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins. https:\/\/doi.org\/101080\/1742525520171372425. 2017;13(10):1075\u20131087. doi:10.1080\/17425255.2017.1372425.","DOI":"10.1080\/17425255.2017.1372425"},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0031","first-page":"473","article-title":"Drug-induced QT prolongation and torsades de pointes","volume":"42","author":"Li","year":"2017","journal-title":"Pharm Ther."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0055","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-019-0314-1","article-title":"Theoretical considerations for direct translation of unbound liver-to-plasma partition coefficient from in vitro to in vivo","volume":"21","author":"Li","year":"2019","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0024","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jcmm.14796","article-title":"CYP2J2\/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice","volume":"24","author":"Li","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0018","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1113\/jphysiol.2001.012896","article-title":"Activation of ATP-sensitive K+ channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes","volume":"537","author":"Lu","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejps.2023.106475_bib0048","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-pharmtox-010617-053110","article-title":"Human induced pluripotent stem cell (hiPSC)-derived cells to assess drug cardiotoxicity: opportunities and problems","volume":"58","author":"Magdy","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0073","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0378-4347(91)80158-9","article-title":"Detection and determination of free and plasma protein-bound astemizole by thin-layer chromatography: a useful technique for bioavailability studies","volume":"567","author":"Mangalan","year":"1991","journal-title":"J. Chromatogr."},{"issue":"4","key":"10.1016\/j.ejps.2023.106475_bib0075","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF02244986","article-title":"Plasma protein binding of risperidone and its distribution in blood","volume":"114","author":"Mannens","year":"1994","journal-title":"Psychopharmacology (Berl.)"},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0060","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/mp4000822","article-title":"Rapid measurement of intracellular unbound drug concentrations","volume":"10","author":"Mateus","year":"2013","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.ejps.2023.106475_bib0030","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1124\/dmd.30.11.1240","article-title":"Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole","volume":"30","author":"Matsumoto","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0063","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/FJC.0b013e3181abc288","article-title":"The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel","volume":"54","author":"McBride","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"16","key":"10.1016\/j.ejps.2023.106475_bib0072","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2165\/00003495-200666160-00009","article-title":"Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting","volume":"66","author":"McKeage","year":"2006","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/bjp.2008.216","article-title":"Arachidonic acid and ion channels: an update","volume":"155","author":"Meves","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2023.106475_bib0008","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1124\/dmd.114.058040","article-title":"The revised human liver cytochrome P450 \u201cPie\u201d: absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics","volume":"42","author":"Michaels","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"21","key":"10.1016\/j.ejps.2023.106475_bib0078","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1001\/jama.1990.03450210088038","article-title":"Torsades de pointes occurring in association with terfenadine use","volume":"264","author":"Monahan","year":"1990","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0027","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ng.129","article-title":"Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease","volume":"40","author":"Monti","year":"2008","journal-title":"Nat. Genet."},{"issue":"21","key":"10.1016\/j.ejps.2023.106475_bib0090","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/01.CIR.102.21.2665","article-title":"Dofetilide","volume":"102","author":"Mounsey","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0098","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/toxsci\/kfy299","article-title":"Evaluation of possible proarrhythmic potency: comparison of the effect of dofetilide, cisapride, sotalol, terfenadine, and verapamil on hERG and Native IKr currents and on cardiac action potential","volume":"168","author":"Orvos","year":"2019","journal-title":"Toxicol. Sci."},{"issue":"24","key":"10.1016\/j.ejps.2023.106475_bib0002","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1074\/jbc.R112.431916","article-title":"Cytochromes P450: roles in diseases","volume":"288","author":"Pikuleva","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1751-2980.2011.00491.x","article-title":"Cisapride: what can we learn from the rise and fall of a prokinetic?","volume":"12","author":"Quigley","year":"2011","journal-title":"J. Dig. Dis."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0084","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/dmd.112.048264","article-title":"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors","volume":"41","author":"Ren","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.ejps.2023.106475_bib0058","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1124\/dmd.116.071837","article-title":"Determination of unbound partition coefficient and in vitro-in vivo extrapolation for SLC13A transporter-mediated uptake","volume":"44","author":"Riccardi","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0052","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.116.074575","article-title":"Novel method to predict in vivo liver-to-plasma K puu for OATP substrates using suspension hepatocytes","volume":"45","author":"Riccardi","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","article-title":"Ondansetron clinical pharmacokinetics","volume":"29","author":"Roila","year":"1995","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0074","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00822.x","article-title":"Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance","volume":"46","author":"Schaber","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106475_bib0069","series-title":"Encyclopedia of Toxicology","first-page":"144","article-title":"Terfenadine","author":"Scharman","year":"2005"},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0108","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/CH-199226","article-title":"NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies","volume":"73","author":"Schulz","year":"2019","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.ejps.2023.106475_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.016","article-title":"Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases","volume":"183","author":"Schunck","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106475_bib0127","article-title":"Physiology, aldosterone","author":"Scott","year":"2022","journal-title":"StatPearls"},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0077","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0272-6386(97)90291-2","article-title":"Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin","volume":"30","author":"Sekkarie","year":"1997","journal-title":"Am. J. Kidney Dis."},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0043","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.hrthm.2005.03.023","article-title":"Refining detection of drug-induced proarrhythmia: QT interval and TRIaD","volume":"2","author":"Shah","year":"2005","journal-title":"Hear Rhythm."},{"issue":"11","key":"10.1016\/j.ejps.2023.106475_bib0041","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00002018-200528110-00003","article-title":"Drugs, QTc interval prolongation and final ICH E14 guideline\u00a0: an important milestone with challenges ahead","volume":"28","author":"Shah","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejps.2023.106475_bib0125","doi-asserted-by":"crossref","unstructured":"Shekhar S., Varghese K., Li M., et\u00a0al. Molecular sciences conflicting roles of 20-HETE in hypertension and stroke. Published online 2019. doi:10.3390\/ijms20184500.","DOI":"10.3390\/ijms20184500"},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40981-021-00475-3","article-title":"Successful treatment of bepridil-induced intraoperative torsades de pointes by isoproterenol infusion","volume":"7","author":"Shimano","year":"2021","journal-title":"JA Clin. Rep."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0061","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003721","article-title":"Molecular mechanisms and new treatment paradigm for atrial fibrillation","volume":"9","author":"Sirish","year":"2016","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0122","first-page":"1","article-title":"Risk of domperidone induced severe ventricular arrhythmia","volume":"10","author":"Song","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0094","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/01.RES.68.3.653","article-title":"Two components of use-dependent block of Na+ current by disopyramide and lidocaine in guinea pig ventricular myocytes","volume":"68","author":"Sunami","year":"1991","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.ejps.2023.106475_bib0117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hup.1258","article-title":"QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone","volume":"27","author":"Suzuki","year":"2012","journal-title":"Hum. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0120","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical studies on drug\u2013drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0057","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/dmd.120.090563","article-title":"Concentration dependence of the unbound partition coefficient Kp uu and its application to correct for exposure-related discrepancies between biochemical and cellular potency of KAT6A inhibitors","volume":"48","author":"Tr\u00fcnkle","year":"2020","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0056","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1208\/s12248-019-0344-8","article-title":"Impact of intracellular concentrations on metabolic drug-drug interaction studies","volume":"21","author":"Treyer","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2023.106475_bib0067","series-title":"Clinical Pharmacology and Biopharmaceutics Review","article-title":"Vandetanib tablets: drug approval package","year":"2010"},{"key":"10.1016\/j.ejps.2023.106475_bib0068","unstructured":"Propulsid cisapride monohydrate tablets: drug approval package. Clinical pharmacology and biopharmaceutics review. U.S. Food and Drug Administration website."},{"key":"10.1016\/j.ejps.2023.106475_bib0062","series-title":"In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry","year":"2020"},{"issue":"4","key":"10.1016\/j.ejps.2023.106475_bib0130","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue","volume":"9","author":"Varga","year":"2017","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0096","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/PL00005167","article-title":"Effect of disopyramide on potassium currents in rabbit ventricular myocytes","volume":"357","author":"Vir\u00e1g","year":"1998","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0115","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S0735-1097(96)00352-X","article-title":"Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole","volume":"28","author":"Vorperian","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejps.2023.106475_bib0126","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.prostaglandins.2016.05.007","article-title":"The role of 20-HETE in cardiovascular diseases and its risk factors","volume":"125","author":"Waldman","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0044","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/toxsci\/kfy270","article-title":"Today's challenges to de-risk and predict drug safety in human \u201cmind-the-gap\u201d","volume":"167","author":"Weaver","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"8","key":"10.1016\/j.ejps.2023.106475_bib0022","doi-asserted-by":"crossref","first-page":"e73490","DOI":"10.1371\/journal.pone.0073490","article-title":"CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy","volume":"8","author":"Westphal","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0124","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10928-021-09744-1","article-title":"How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology - model-based case study","volume":"48","author":"Wi\u015bniowska","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"7","key":"10.1016\/j.ejps.2023.106475_bib0009","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1074\/jbc.271.7.3460","article-title":"Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart","volume":"271","author":"Wu","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/1389200215666140908095647","article-title":"Research\/review: insights into the mutation-induced dysfunction of arachidonic acid metabolism from modeling of human CYP2J2","volume":"15","author":"Xia","year":"2014","journal-title":"Curr. Drug Metab."},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1469-7793.1998.777bp.x","article-title":"Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells","volume":"508","author":"Xiao","year":"1998","journal-title":"J. Physiol."},{"issue":"1\u20134","key":"10.1016\/j.ejps.2023.106475_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.prostaglandins.2006.05.023","article-title":"Cyclic AMP-dependent modulation of cardiac l-type Ca2+ and transient outward K+ channel activities by epoxyeicosatrienoic acids","volume":"82","author":"Xiao","year":"2007","journal-title":"Prostagland. Other Lipid Mediat."},{"key":"10.1016\/j.ejps.2023.106475_bib0025","series-title":"Proceeding of the National Academy of Science U S A","first-page":"18733","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006"},{"issue":"3","key":"10.1016\/j.ejps.2023.106475_bib0093","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.93.3.407","article-title":"Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence","volume":"93","author":"Yang","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejps.2023.106475_bib0092","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.RES.73.2.351","article-title":"Block of transient outward-type cloned cardiac K+ channel currents by quinidine","volume":"73","author":"Yatani","year":"1993","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0007","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"issue":"5","key":"10.1016\/j.ejps.2023.106475_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(25)09539-2","article-title":"CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance","volume":"50","author":"Zeldin","year":"1996","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0105","article-title":"Effect of cytochrome b5 content on the activity of polymorphic CYP1A2, 2B6, and 2E1 in human liver microsomes","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.ejps.2023.106475_bib0104","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1124\/dmd.116.069849","article-title":"Correlation of cytochrome P450 oxidoreductase expression with the expression of 10 isoforms of cytochrome P450 in human liver","volume":"44","author":"Zhang","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.ejps.2023.106475_bib0114","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1540-8167.1999.tb00264.x","article-title":"Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole","volume":"10","author":"Zhou","year":"1999","journal-title":"J. Cardiovasc. Electrophysiol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723001057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723001057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:06:37Z","timestamp":1760529997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723001057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":130,"alternative-id":["S0928098723001057"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106475","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106475"}}